Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses

Seminars in Cancer Biology

Volumn 26, Issue , 2014, Pages 30-42

  Wallace, Nicholas A ^a   Galloway, Denise A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

DNA damage repair; HPV; HPV replication

Indexed keywords

ATR PROTEIN; CELL DNA; GLYCOPROTEIN E1; GLYCOPROTEIN E2; PROTEIN E6; PROTEIN E7; PROTEIN P53; TRANSCRIPTION FACTOR E2F; ONCOPROTEIN; VIRAL PROTEIN; ATM PROTEIN;

APOPTOSIS; CELL CYCLE PROGRESSION; DEACETYLATION; DNA DAMAGE; DNA REPAIR; E6 GENE; E7 GENE; G1 PHASE CELL CYCLE CHECKPOINT; GENOMIC INSTABILITY; HISTONE ACETYLATION; HUMAN; NONHUMAN; REVIEW; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; VIRUS GENOME; VIRUS INHIBITION; VIRUS ONCOGENE; VIRUS REPLICATION; WART VIRUS; ALPHAPAPILLOMAVIRUS; GENETICS; METABOLISM; PAPILLOMAVIRUS INFECTION; PHYSIOLOGY; VIROLOGY; CELL DEATH; GENE AMPLIFICATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; VIRUS MORPHOLOGY;

ALPHAPAPILLOMAVIRUS; DNA DAMAGE; DNA REPAIR; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84901854470     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.12.003     Document Type: Review

References (197)

1. Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993, 362:709-715.
2. Alt F.W., Zhang Y., Meng F.L., Guo C., Schwer B. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell 2013, 152:417-429.
3. Boyer J., Rohleder K., Ketner G. Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 1999, 263:307-312.
4. Evans J.D., Hearing P. Relocalization of the Mre11-Rad50-Nbs1 complex by the adenovirus E4 ORF3 protein is required for viral replication. J Virol 2005, 79:6207-6215.
5. Stracker T.H., Carson C.T., Weitzman M.D. Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 2002, 418:348-352.
6. Liang X., Pickering M.T., Cho N.H., Chang H., Volkert M.R., Kowalik T.F., et al. Deregulation of DNA damage signal transduction by herpesvirus latency-associated M2. J Virol 2006, 80:5862-5874.
7. Wilkinson D.E., Weller S.K. Herpes simplex virus type I disrupts the ATR-dependent DNA-damage response during lytic infection. J Cell Sci 2006, 119:2695-2703.
8. Lees-Miller S.P., Long M.C., Kilvert M.A., Lam V., Rice S.A., Spencer C.A. Attenuation of DNA-dependent protein kinase activity and its catalytic subunit by the herpes simplex virus type 1 transactivator ICP0. J Virol 1996, 70:7471-7477.
9. Parkinson J., Lees-Miller S.P., Everett R.D. Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J Virol 1999, 73:650-657.
10. Di Pasquale G., Stacey S.N. Adeno-associated virus Rep78 protein interacts with protein kinase A and its homolog PRKX and inhibits CREB-dependent transcriptional activation. J Virol 1998, 72:7916-7925.
11. Lee T.H., Elledge S.J., Butel J.S. Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. J Virol 1995, 69:1107-1114.
12. Becker S.A., Lee T.H., Butel J.S., Slagle B.L. Hepatitis B virus X protein interferes with cellular DNA repair. J Virol 1998, 72:266-272.
13. Shin Y.C., Nakamura H., Liang X., Feng P., Chang H., Kowalik T.F., et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol 2006, 80:2257-2266.
14. Darbinyan A., Siddiqui K.M., Slonina D., Darbinian N., Amini S., White M.K., et al. Role of JC virus agnoprotein in DNA repair. J Virol 2004, 78:8593-8600.
15. Shi Y., Dodson G.E., Shaikh S., Rundell K., Tibbetts R.S. Ataxia-telangiectasia-mutated (ATM) is a T-antigen kinase that controls SV40 viral replication in vivo. J Biol Chem 2005, 280:40195-40200.
16. Shirata N., Kudoh A., Daikoku T., Tatsumi Y., Fujita M., Kiyono T., et al. Activation of ataxia telangiectasia-mutated DNA damage checkpoint signal transduction elicited by herpes simplex virus infection. J Biol Chem 2005, 280:30336-30341.
17. Wilkinson D.E., Weller S.K. Recruitment of cellular recombination and repair proteins to sites of herpes simplex virus type 1 DNA replication is dependent on the composition of viral proteins within prereplicative sites and correlates with the induction of the DNA damage response. J Virol 2004, 78:4783-4796.
18. Lilley C.E., Carson C.T., Muotri A.R., Gage F.H., Weitzman M.D. DNA repair proteins affect the lifecycle of herpes simplex virus 1. Proc Natl Acad Sci U S A 2005, 102:5844-5849.
19. Dey D., Dahl J., Cho S., Benjamin T.L. Induction and bypass of p53 during productive infection by polyomavirus. J Virol 2002, 76:9526-9532.
20. Dahl J., You J., Benjamin T.L. Induction and utilization of an ATM signaling pathway by polyomavirus. J Virol 2005, 79:13007-13017.
21. Kudoh A., Fujita M., Zhang L., Shirata N., Daikoku T., Sugaya Y., et al. Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J Biol Chem 2005, 280:8156-8163.
22. Daikoku T., Kudoh A., Sugaya Y., Iwahori S., Shirata N., Isomura H., et al. Postreplicative mismatch repair factors are recruited to Epstein-Barr virus replication compartments. J Biol Chem 2006, 281:11422-11430.
23. Jault F.M., Jault J.M., Ruchti F., Fortunato E.A., Clark C., Corbeil J., et al. Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J Virol 1995, 69:6697-6704.
24. Casavant N.C., Luo M.H., Rosenke K., Winegardner T., Zurawska A., Fortunato E.A. Potential role for p53 in the permissive life cycle of human cytomegalovirus. J Virol 2006, 80:8390-8401.
25. Gaspar M., Shenk T. Human cytomegalovirus inhibits a DNA damage response by mislocalizing checkpoint proteins. Proc Natl Acad Sci U S A 2006, 103:2821-2826.
26. Luo M.H., Rosenke K., Czornak K., Fortunato E.A. Human cytomegalovirus disrupts both ataxia telangiectasia mutated protein (ATM)- and ATM-Rad3-related kinase-mediated DNA damage responses during lytic infection. J Virol 2007, 81:1934-1950.
27. Taylor T.J., Knipe D.M. Proteomics of herpes simplex virus replication compartments: association of cellular DNA replication, repair, recombination, and chromatin remodeling proteins with ICP8. J Virol 2004, 78:5856-5866.
28. Fradet-Turcotte A., Bergeron-Labrecque F., Moody C.A., Lehoux M., Laimins L.A., Archambault J. Nuclear accumulation of the papillomavirus E1 helicase blocks S-phase progression and triggers an ATM-dependent DNA damage response. J Virol 2011, 85:8996-9012.
29. Reinson T., Toots M., Kadaja M., Pipitch R., Allik M., Ustav E., et al. Engagement of the ATR-dependent DNA damage response at the human papillomavirus 18 replication centers during the initial amplification. J Virol 2013, 87:951-964.
30. Lilley C.E., Schwartz R.A., Weitzman M.D. Using or abusing: viruses and the cellular DNA damage response. Trends Microbiol 2007, 15:119-126.
31. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005, 32(Suppl. 1):S7-S15.
32. Stenlund A. Initiation of DNA replication: lessons from viral initiator proteins. Nature Rev Mol Cell Biol 2003, 4:777-785.
33. Ma T., Zou N., Lin B.Y., Chow L.T., Harper J.W. Interaction between cyclin-dependent kinases and human papillomavirus replication-initiation protein E1 is required for efficient viral replication. Proc Natl Acad Sci U S A 1999, 96:382-387.
34. Fradet-Turcotte A., Moody C., Laimins L.A., Archambault J. Nuclear export of human papillomavirus type 31 E1 is regulated by Cdk2 phosphorylation and required for viral genome maintenance. J Virol 2010, 84:11747-11760.
35. Sakakibara N., Mitra R., McBride A.A. The papillomavirus E1 helicase activates a cellular DNA damage response in viral replication foci. J Virol 2011, 85:8981-8995.
36. Kastan M.B., Lim D.S., Kim S.T., Xu B., Canman C. Multiple signaling pathways involving ATM. Cold Spring Harb Symp Quant Biol 2000, 65:521-526.
37. Flynn R.L., Zou L. ATR: a master conductor of cellular responses to DNA replication stress. Trends Biochem Sci 2011, 36:133-140.
38. Boner W., Taylor E.R., Tsirimonaki E., Yamane K., Campo M.S., Morgan I.M. A Functional interaction between the human papillomavirus 16 transcription/replication factor E2 and the DNA damage response protein TopBP1. J Biol Chem 2002, 277:22297-22303.
39. Donaldson M.M., Boner W., Morgan I.M. TopBP1 regulates human papillomavirus type 16 E2 interaction with chromatin. J Virol 2007, 81:4338-4342.
40. Lehman C.W., Botchan M.R. Segregation of viral plasmids depends on tethering to chromosomes and is regulated by phosphorylation. Proc Natl Acad Sci U S A 1998, 95:4338-4343.
41. Bernat A., Avvakumov N., Mymryk J.S., Banks L. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 2003, 22:7871-7881.
42. Lee D., Hwang S.G., Kim J., Choe J. Functional interaction between p/CAF and human papillomavirus E2 protein. J Biol Chem 2002, 277:6483-6489.
43. Lee D., Lee B., Kim J., Kim D.W., Choe J. cAMP response element-binding protein-binding protein binds to human papillomavirus E2 protein and activates E2-dependent transcription. J Biol Chem 2000, 275:7045-7051.
44. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998, 12:2831-2841.
45. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999, 19:1202-1209.
46. Zhao Y., Lu S., Wu L., Chai G., Wang H., Chen Y., et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006, 26:2782-2790.
47. Wallace N.A., Robinson K., Howie H.L., Galloway D.A. HPV 5 and 8 E6 Abrogate ATR Activity Resulting in Increased Persistence of UVB Induced DNA Damage. PLoS Pathog 2012, 8:e1002807.
48. Wallace N.A., Gasior S.L., Faber Z.J., Howie H.L., Deininger P.L., Galloway D.A. HPV 5 and 8 E6 expression reduces ATM protein levels and attenuates LINE-1 retrotransposition. Virology 2013, 443(1):69-79.
49. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998, 281:1674-1677.
50. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-334.
51. Massimi P., Pim D., Bertoli C., Bouvard V., Banks L. Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 1999, 18:7748-7754.
52. Thierry F., Demeret C. Direct activation of caspase 8 by the proapoptotic E2 protein of HPV18 independent of adaptor proteins. Cell Death Differ 2008, 15:1356-1363.
53. Webster K., Parish J., Pandya M., Stern P.L., Clarke A.R., Gaston K. The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 2000, 275:87-94.
54. Liu J.S., Kuo S.R., Broker T.R., Chow L.T. The functions of human papillomavirus type 11 E1, E2, and E2C proteins in cell-free DNA replication. J Biol Chem 1995, 270:27283-27291.
55. Gillespie K.A., Mehta K.P., Laimins L.A., Moody C.A. Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. J Virol 2012, 86:9520-9526.
56. Kottemann M.C., Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 2013, 493:356-363.
57. Hoskins E.E., Morreale R.J., Werner S.P., Higginbotham J.M., Laimins L.A., Lambert P.F., et al. The fanconi anemia pathway limits human papillomavirus replication. J Virol 2012, 86:8131-8138.
58. Hoskins E.E., Morris T.A., Higginbotham J.M., Spardy N., Cha E., Kelly P., et al. Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. Oncogene 2009, 28:674-685.
59. Kutler D.I., Auerbach A.D., Satagopan J., Giampietro P.F., Batish S.D., Huvos A.G., et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol - Head Neck Surg 2003, 129:106-112.
60. Kutler D.I., Wreesmann V.B., Goberdhan A., Ben-Porat L., Satagopan J., Ngai I., et al. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. J National Cancer Inst 2003, 95:1718-1721.
61. Park J.W., Pitot H.C., Strati K., Spardy N., Duensing S., Grompe M., et al. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Res 2010, 70:9959-9968.
62. Moody C.A., Fradet-Turcotte A., Archambault J., Laimins L.A. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc Natl Acad Sci U S A 2007, 104:19541-19546.
63. Moody C.A., Laimins L.A. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation. PLoS Pathog 2009, 5:e1000605.
64. Howie H.L., Katzenellenbogen R.A., Galloway D.A. Papillomavirus E6 proteins. Virology 2009, 384:324-334.
65. McLaughlin-Drubin M.E., Munger K. The human papillomavirus E7 oncoprotein. Virology 2009, 384:335-344.
66. Frolov M.V., Dyson N.J. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 2004, 117:2173-2181.
67. Dyson N., Guida P., Munger K., Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J Virol 1992, 66:6893-6902.
68. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
69. Munger K., Werness B.A., Dyson N., Phelps W.C., Harlow E., Howley P.M. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. Embo J 1989, 8:4099-4105.
70. Huang P.S., Patrick D.R., Edwards G., Goodhart P.J., Huber H.E., Miles L., et al. Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein. Mol Cell Biol 1993, 13:953-960.
71. Wu E.W., Clemens K.E., Heck D.V., Munger K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J Virol 1993, 67:2402-2407.
72. Chellappan S., Kraus V.B., Kroger B., Munger K., Howley P.M., Phelps W.C., et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci U S A 1992, 89:4549-4553.
73. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989, 63:4417-4421.
74. Gage J.R., Meyers C., Wettstein F.O. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J Virol 1990, 64:723-730.
75. Boyer S.N., Wazer D.E., Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996, 56:4620-4624.
76. Jones D.L., Thompson D.A., Munger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 1997, 239:97-107.
77. Demers G.W., Foster S.A., Halbert C.L., Galloway D.A. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci U S A 1994, 91:4382-4386.
78. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., et al. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 2007, 81:9737-9747.
79. Gonzalez S.L., Stremlau M., He X., Basile J.R., Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 2001, 75:7583-7591.
80. Zhang B., Chen W., Roman A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc Natl Acad Sci U S A 2006, 103:437-442.
81. Sang B.C., Barbosa M.S. Single amino acid substitutions in low-risk human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the high-risk HPV E7 oncoproteins. Proc Natl Acad Sci U S A 1992, 89:8063-8067.
82. Heck D.V., Yee C.L., Howley P.M., Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992, 89:4442-4446.
83. Hwang S.G., Lee D., Kim J., Seo T., Choe J. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J Biol Chem 2002, 277:2923-2930.
84. McLaughlin-Drubin M.E., Huh K.W., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J Virol 2008, 82:8695-8705.
85. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997, 11:2090-2100.
86. Jones D.L., Alani R.M., Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 1997, 11:2101-2111.
87. Helt A.M., Funk J.O., Galloway D.A. Inactivation of both the retinoblastoma tumor suppressor and p21 by the human papillomavirus type 16 E7 oncoprotein is necessary to inhibit cell cycle arrest in human epithelial cells. J Virol 2002, 76:10559-10568.
88. Jones D.L., Thompson D.A., Suh-Burgmann E., Grace M., Munger K. Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent cellular DNA damage response pathway. Virology 1999, 258:406-414.
89. Zerfass-Thome K., Zwerschke W., Mannhardt B., Tindle R., Botz J.W., Jansen-Durr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996, 13:2323-2330.
90. Jian Y., Schmidt-Grimminger D.C., Chien W.M., Wu X., Broker T.R., Chow L.T. Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. Oncogene 1998, 17:2027-2038.
91. Ruesch M.N., Laimins L.A. Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J Virol 1997, 71:5570-5578.
92. Noya F., Chien W.M., Broker T.R. Chow LT. p21cip1 Degradation in differentiated keratinocytes is abrogated by costabilization with cyclin E induced by human papillomavirus E7. J Virol 2001, 75:6121-6134.
93. Nguyen C.L., Munger K. Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology 2008, 380:21-25.
94. He W., Staples D., Smith C., Fisher C. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J Virol 2003, 77:10566-10574.
95. McIntyre M.C., Ruesch M.N., Laimins L.A. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology 1996, 215:73-82.
96. Nguyen D.X., Westbrook T.F., McCance D.J. Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest. J Virol 2002, 76:619-632.
97. Longworth M.S., Laimins L.A. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol 2004, 78:3533-3541.
98. Longworth M.S., Wilson R., Laimins L.A. HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. Embo J 2005, 24:1821-1830.
99. Brehm A., Nielsen S.J., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. Embo J 1999, 18:2449-2458.
100. Avvakumov N., Torchia J., Mymryk J.S. Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 2003, 22:3833-3841.
101. Chen J.J., Hong Y., Rustamzadeh E., Baleja J.D., Androphy E.J. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem 1998, 273:13537-13544.
102. Huang S.M., McCance D.J. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J Virol 2002, 76:8710-8721.
103. Baldwin A., Huh K.W., Munger K. Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function. J Virol 2006, 80:6669-6677.
104. Spencer T.E., Jenster G., Burcin M.M., Allis C.D., Zhou J., Mizzen C.A., et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997, 389:194-198.
105. Demers G.W., Halbert C.L., Galloway D.A. Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 1994, 198:169-174.
106. Jones D.L., Munger K. Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 1997, 71:2905-2912.
107. Seavey S.E., Holubar M., Saucedo L.J., Perry M.E. The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). J Virol 1999, 73:7590-7598.
108. Hengstermann A., Linares L.K., Ciechanover A., Whitaker N.J., Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci U S A 2001, 98:1218-1223.
109. Eichten A., Westfall M., Pietenpol J.A., Munger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology 2002, 295:74-85.
110. Slebos R.J., Lee M.H., Plunkett B.S., Kessis T.D., Williams B.O., Jacks T., et al. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A 1994, 91:5320-5324.
111. Hickman E.S., Picksley S.M., Vousden K.H. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 1994, 9:2177-2181.
112. Vousden K.H., Vojtesek B., Fisher C., Lane D. HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Oncogene 1993, 8:1697-1702.
113. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000, 14:1448-1459.
114. Liu S., Bekker-Jensen S., Mailand N., Lukas C., Bartek J., Lukas J. Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Mol Cell Biol 2006, 26:6056-6064.
115. Spardy N., Covella K., Cha E., Hoskins E.E., Wells S.I., Duensing A., et al. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res 2009, 69:7022-7029.
116. Duensing S., Munger K. Human papillomaviruses and centrosome duplication errors: modeling the origins of genomic instability. Oncogene 2002, 21:6241-6248.
117. Nguyen C.L., McLaughlin-Drubin M.E., Munger K. Delocalization of the microtubule motor Dynein from mitotic spindles by the human papillomavirus E7 oncoprotein is not sufficient for induction of multipolar mitoses. Cancer Res 2008, 68:8715-8722.
118. Nguyen C.L., Munger K. Human papillomavirus E7 protein deregulates mitosis via an association with nuclear mitotic apparatus protein 1. J Virol 2009, 83:1700-1707.
119. Asai D.J., Koonce M.P. The dynein heavy chain: structure, mechanics and evolution. Trends Cell Biol 2001, 11:196-202.
120. Fan X., Liu Y., Heilman S.A., Chen J.J. Human papillomavirus E7 induces rereplication in response to DNA damage. J Virol 2013, 87:1200-1210.
121. Hashida T., Yasumoto S. Induction of chromosome abnormalities in mouse and human epidermal keratinocytes by the human papillomavirus type 16 E7 oncogene. J Gen Virol 1991, 72(Pt 7):1569-1577.
122. Duensing S., Lee L.Y., Duensing A., Basile J., Piboonniyom S., Gonzalez S., et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci U S A 2000, 97:10002-10007.
123. Duensing S., Duensing A., Flores E.R., Do A., Lambert P.F., Munger K. Centrosome abnormalities and genomic instability by episomal expression of human papillomavirus type 16 in raft cultures of human keratinocytes. J Virol 2001, 75:7712-7716.
124. Duensing A., Liu Y., Perdreau S.A., Kleylein-Sohn J., Nigg E.A., Duensing S. Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates. Oncogene 2007, 26:6280-6288.
125. Duensing S., Munger K. Human papillomavirus type 16 E7 oncoprotein can induce abnormal centrosome duplication through a mechanism independent of inactivation of retinoblastoma protein family members. J Virol 2003, 77:12331-12335.
126. Nguyen C.L., Eichwald C., Nibert M.L., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with the centrosomal component gamma-tubulin. J Virol 2007, 81:13533-13543.
127. Duensing S., Duensing A., Lee D.C., Edwards K.M., Piboonniyom S.O., Manuel E., et al. Cyclin-dependent kinase inhibitor indirubin-3'-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 2004, 23:8206-8215.
128. Duensing A., Liu Y., Tseng M., Malumbres M., Barbacid M., Duensing S. Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene 2006, 25:2943-2949.
129. Duensing S., Duensing A., Crum C.P., Munger K. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res 2001, 61:2356-2360.
130. Spardy N., Duensing A., Charles D., Haines N., Nakahara T., Lambert P.F., et al. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. J Virol 2007, 81:13265-13270.
131. Spardy N., Duensing A., Hoskins E.E., Wells S.I., Duensing S. HPV-16 E7 reveals a link between DNA replication stress, fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies. Cancer Res 2008, 68:9954-9963.
132. Zhang Y., Fan S., Meng Q., Ma Y., Katiyar P., Schlegel R., et al. BRCA1 interaction with human papillomavirus oncoproteins. J Biol Chem 2005, 280:33165-33177.
133. Stoppler H., Stoppler M.C., Johnson E., Simbulan-Rosenthal C.M., Smulson M.E., Iyer S., et al. The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis. Oncogene 1998, 17:1207-1214.
134. Rogoff H.A., Pickering M.T., Frame F.M., Debatis M.E., Sanchez Y., Jones S., et al. Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol Cell Biol 2004, 24:2968-2977.
135. Eichten A., Rud D.S., Grace M., Piboonniyom S.O., Zacny V., Munger K. Molecular pathways executing the trophic sentinel response in HPV-16 E7-expressing normal human diploid fibroblasts upon growth factor deprivation. Virology 2004, 319:81-93.
136. White E., Cipriani R., Sabbatini P. Denton A. Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. J Virol 1991, 65:2968-2978.
137. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
138. Zhou X., Munger K. Expression of the human papillomavirus type 16 E7 oncoprotein induces an autophagy-related process and sensitizes normal human keratinocytes to cell death in response to growth factor deprivation. Virology 2009, 385:192-197.
139. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
140. Scheffner M., Munger K., Byrne J.C., Howley P.M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991, 88:5523-5527.
141. Huibregtse J.M., Scheffner M., Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. Embo J 1991, 10:4129-4135.
142. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
143. Huibregtse J.M., Scheffner M., Howley P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 1993, 13:4918-4927.
144. Brimer N., Lyons C. Vande Pol SB. Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein. Virology 2007, 358:303-310.
145. Mesplede T., Gagnon D., Bergeron-Labrecque F., Azar I., Senechal H., Coutlee F., et al. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol 2012, 86:94-107.
146. Massimi P., Shai A., Lambert P., Banks L. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene 2008, 27:1800-1804.
147. Gu Z., Pim D., Labrecque S., Banks L., Matlashewski G. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene 1994, 9:629-633.
148. Crook T., Tidy J.A., Vousden K.H. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991, 67:547-556.
149. Thomas M.C., Chiang C.M. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 2005, 17:251-264.
150. Lechner M.S., Laimins L.A. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 1994, 68:4262-4273.
151. Mantovani F., Banks L. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene 1999, 18:3309-3315.
152. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
153. Patel D., Huang S.M., Baglia L.A., McCance D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. Embo J 1999, 18:5061-5072.
154. Zimmermann H., Koh C.H., Degenkolbe R., O'Connor M.J., Muller A., Steger G., et al. Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53. J Gen Virol 2000, 81:2617-2623.
155. Kumar A., Zhao Y., Meng G., Zeng M., Srinivasan S., Delmolino L.M., et al. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol 2002, 22:5801-5812.
156. Sekaric P., Shamanin V.A., Luo J., Androphy E.J. hAda3 regulates p14ARF-induced p53 acetylation and senescence. Oncogene 2007, 26:6261-6268.
157. Wang T., Kobayashi T., Takimoto R., Denes A.E., Snyder E.L., el-Deiry W.S., et al. hADA3 is required for p53 activity. Embo J 2001, 20:6404-6413.
158. Shamanin V.A., Sekaric P., Androphy E.J. hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells. J Virol 2008, 82:3912-3920.
159. Howie H.L., Koop J.I., Weese J., Robinson K., Wipf G., Kim L., et al. Beta-HPV 5 and 8 E6 Promote p300 Degradation by Blocking AKT/p300 Association. PLoS Pathog 2011, 7:e1002211.
160. Srivenugopal K.S., Ali-Osman F. The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene 2002, 21:5940-5945.
161. Iftner T., Elbel M., Schopp B., Hiller T., Loizou J.I., Caldecott K.W., et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. Embo J 2002, 21:4741-4748.
162. Yim E.K., Lee K.H., Myeong J., Tong S.Y., Um S.J., Park J.S. Novel interaction between HPV E6 and BARD1 (BRCA1-associated ring domain 1) and its biologic roles. DNA Cell Biol 2007, 26:753-761.
163. Shin K.H., Ahn J.H., Kang M.K., Lim P.K., Yip F.K., Baluda M.A., et al. HPV-16 E6 oncoprotein impairs the fidelity of DNA end-joining via p53-dependent and -independent pathways. Int J Oncol 2006, 28:209-215.
164. Giampieri S., Storey A. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer 2004, 90:2203-2209.
165. Hawkins D.S., Demers G.W., Galloway D.A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996, 56:892-898.
166. Havre P.A., Yuan J., Hedrick L., Cho K.R., Glazer P.M. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995, 55:4420-4424.
167. Malanchi I., Accardi R., Diehl F., Smet A., Androphy E., Hoheisel J., et al. Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. J Virol 2004, 78:13769-13778.
168. Kessis T.D., Slebos R.J., Nelson W.G., Kastan M.B., Plunkett B.S., Han S.M., et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A 1993, 90:3988-3992.
169. Foster S.A., Demers G.W., Etscheid B.G., Galloway D.A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 1994, 68:5698-5705.
170. Kaufmann W.K., Schwartz J.L., Hurt J.C., Byrd L.L., Galloway D.A., Levedakou E., et al. Inactivation of G2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ 1997, 8:1105-1114.
171. Yuan C.H., Filippova M., Duerksen-Hughes P. Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses 2012, 4:3831-3850.
172. Muench P., Probst S., Schuetz J., Leiprecht N., Busch M., Wesselborg S., et al. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Res 2010, 70:6913-6924.
173. Pan H., Griep A.E. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Dev 1995, 9:2157-2169.
174. Pan H., Griep A.E. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 1994, 8:1285-1299.
175. Steller M.A., Zou Z., Schiller J.T., Baserga R. Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor. Cancer Res 1996, 56:5087-5091.
176. Shen Y. White E. p53-dependent apoptosis pathways. Adv Cancer Res 2001, 82:55-84.
177. Thomas M., Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998, 17:2943-2954.
178. Thomas M., Banks L. Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol 1999, 80(Pt 6):1513-1517.
179. Jackson S., Harwood C., Thomas M., Banks L., Storey A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000, 14:3065-3073.
180. Underbrink M.P., Howie H.L., Bedard K.M., Koop J.I., Galloway D.A. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 2008, 82:10408-10417.
181. Du J., Chen G.G., Vlantis A.C., Chan P.K., Tsang R.K., van Hasselt C.A. Resistance to apoptosis of HPV 16-infected laryngeal cancer cells is associated with decreased Bak and increased Bcl-2 expression. Cancer Lett 2004, 205:81-88.
182. Struijk L., van der Meijden E., Kazem S., ter Schegget J., de Gruijl F.R., Steenbergen R.D., et al. Specific betapapillomaviruses associated with squamous cell carcinoma of the skin inhibit UVB-induced apoptosis of primary human keratinocytes. J Gen Virol 2008, 89:2303-2314.
183. Leverrier S., Bergamaschi D., Ghali L., Ola A., Warnes G., Akgul B., et al. Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. Apoptosis 2007, 12:549-560.
184. Jong J.E., Jeong K.W., Shin H., Hwang L.R., Lee D., Seo T. Human papillomavirus type 16 E6 protein inhibits DNA fragmentation via interaction with DNA fragmentation factor 40. Cancer Lett 2012, 324:109-117.
185. James M.A., Lee J.H., Klingelhutz A.J. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol 2006, 80:5301-5307.
186. Yuan H., Fu F., Zhuo J., Wang W., Nishitani J., An D.S., et al. Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis. Oncogene 2005, 24:5069-5078.
187. Borbely A.A., Murvai M., Konya J., Beck Z., Gergely L., Li F., et al. Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J Gen Virol 2006, 87:287-294.
188. Tomlins C., Storey A. Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis. Carcinogenesis 2010, 31:2155-2164.
189. Kazem S., van der Meijden E., Struijk L., de Gruijl F.R., Feltkamp M.C. Human papillomavirus 8 E6 disrupts terminal skin differentiation and prevents pro-Caspase-14 cleavage. Virus Res 2012, 163:609-616.
190. Garnett T.O., Duerksen-Hughes P.J. Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch Virol 2006, 151:2321-2335.
191. Filippova M., Johnson M.M., Bautista M., Filippov V., Fodor N., Tungteakkhun S.S., et al. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 2007, 81:4116-4129.
192. Tungteakkhun S.S., Filippova M., Fodor N., Duerksen-Hughes P.J. The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain. J Virol 2010, 84:1453-1463.
193. Li G.L., Jiang W., Xia Q., Chen S.H., Ge X.R., Gui S.Q., et al. HPV E6 down-regulation and apoptosis induction of human cervical cancer cells by a novel lipid-soluble extract (PE) from Pinellia pedatisecta Schott in vitro. J Ethnopharmacol 2010, 132:56-64.
194. Qi Z., Xu X., Zhang B., Li Y., Liu J., Chen S., et al. Effect of simultaneous silencing of HPV-18 E6 and E7 on inducing apoptosis in HeLa cells. Biochem Cell Biol 2010, 88:697-704.
195. Zhou J., Peng C., Li B., Wang F., Zhou C., Hong D., et al. Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Gynecol Oncol 2012, 124:296-302.
196. Desaintes C., Demeret C., Goyat S., Yaniv M., Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. Embo J 1997, 16:504-514.
197. Desaintes C., Goyat S., Garbay S., Yaniv M., Thierry F. Papillomavirus E2 induces p53-independent apoptosis in HeLa cells. Oncogene 1999, 18:4538-4545.